JP2004504317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504317A5 JP2004504317A5 JP2002512174A JP2002512174A JP2004504317A5 JP 2004504317 A5 JP2004504317 A5 JP 2004504317A5 JP 2002512174 A JP2002512174 A JP 2002512174A JP 2002512174 A JP2002512174 A JP 2002512174A JP 2004504317 A5 JP2004504317 A5 JP 2004504317A5
- Authority
- JP
- Japan
- Prior art keywords
- trifluoro
- benzyloxymethyl
- thiol
- pyrrolidine
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 15
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 7
- 208000010412 Glaucoma Diseases 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 206010040047 Sepsis Diseases 0.000 claims description 7
- 206010040070 Septic Shock Diseases 0.000 claims description 7
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 7
- 206010052779 Transplant rejections Diseases 0.000 claims description 7
- 206010003119 arrhythmia Diseases 0.000 claims description 7
- 230000006793 arrhythmia Effects 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 7
- 239000000824 cytostatic agent Substances 0.000 claims description 7
- 230000001085 cytostatic effect Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 7
- 208000017169 kidney disease Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 208000031225 myocardial ischemia Diseases 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 201000011461 pre-eclampsia Diseases 0.000 claims description 7
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 7
- 230000029663 wound healing Effects 0.000 claims description 7
- 208000002249 Diabetes Complications Diseases 0.000 claims description 6
- 206010012655 Diabetic complications Diseases 0.000 claims description 6
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 claims description 6
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 claims description 6
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 6
- 230000005906 menstruation Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 235000015220 hamburgers Nutrition 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 102000004157 Hydrolases Human genes 0.000 claims description 3
- 108090000604 Hydrolases Proteins 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- -1 diarylalkyl Chemical group 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 5
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 3
- 125000005120 alkyl cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000005127 aryl alkoxy alkyl group Chemical group 0.000 claims 3
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 3
- 238000010511 deprotection reaction Methods 0.000 claims 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 3
- LFNXJOQDRKYPCI-LMRHVHIWSA-N (3r,5s)-1-(5-ethylpyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=CC(CC)=CN=C1N1[C@H](COCC=2C(=CC(F)=C(F)C=2)F)C[C@@H](S)C1 LFNXJOQDRKYPCI-LMRHVHIWSA-N 0.000 claims 2
- XRXDLCUAVFZZIZ-ZWKOTPCHSA-N (3r,5s)-1-(5-phenylpyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=CC(=CN=2)C=2C=CC=CC=2)C[C@H](S)C1 XRXDLCUAVFZZIZ-ZWKOTPCHSA-N 0.000 claims 2
- QJOIUQJMBBQXGO-LDXVYITESA-N (3r,5s)-1-(5-propylpyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=CC(CCC)=CN=C1N1[C@H](COCC=2C(=CC(F)=C(F)C=2)F)C[C@@H](S)C1 QJOIUQJMBBQXGO-LDXVYITESA-N 0.000 claims 2
- HHQGKVFJHXBAAD-JKSUJKDBSA-N (3r,5s)-1-(5-pyridin-2-ylpyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=CC(=CN=2)C=2N=CC=CC=2)C[C@H](S)C1 HHQGKVFJHXBAAD-JKSUJKDBSA-N 0.000 claims 2
- NQHHCMKGFMKOFU-DLBZAZTESA-N (3r,5s)-1-(6-phenylpyridazin-3-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=NC(=CC=2)C=2C=CC=CC=2)C[C@H](S)C1 NQHHCMKGFMKOFU-DLBZAZTESA-N 0.000 claims 2
- LDWBMEMUYZSWCV-ZVWHLABXSA-N (3r,5s)-1-pyrimidin-2-yl-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=CC=CN=2)C[C@H](S)C1 LDWBMEMUYZSWCV-ZVWHLABXSA-N 0.000 claims 2
- KDBBCOCPRDFAAG-JHEYCYPBSA-N 2,2,2-trifluoroacetic acid;(3r,5s)-1-[5-(trifluoromethyl)pyridin-2-yl]-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound OC(=O)C(F)(F)F.C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=CC(=CC=2)C(F)(F)F)C[C@H](S)C1 KDBBCOCPRDFAAG-JHEYCYPBSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000005116 aryl carbamoyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- VKCDHWFZESIXBC-MCJVGQIASA-N (3r,5s)-1-(2-anilinopyrimidin-4-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=C(NC=3C=CC=CC=3)N=CC=2)C[C@H](S)C1 VKCDHWFZESIXBC-MCJVGQIASA-N 0.000 claims 1
- IPMQDYQBJGYCOR-WDEREUQCSA-N (3r,5s)-1-(2-chloropyrimidin-4-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=C(Cl)N=CC=2)C[C@H](S)C1 IPMQDYQBJGYCOR-WDEREUQCSA-N 0.000 claims 1
- XPRQARNOXVFIAN-NWDGAFQWSA-N (3r,5s)-1-(2-methoxypyrimidin-4-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound COC1=NC=CC(N2[C@@H](C[C@@H](S)C2)COCC=2C(=CC(F)=C(F)C=2)F)=N1 XPRQARNOXVFIAN-NWDGAFQWSA-N 0.000 claims 1
- AYBXHWXTWCIHTP-NWDGAFQWSA-N (3r,5s)-1-(2-methylsulfanylpyrimidin-4-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound CSC1=NC=CC(N2[C@@H](C[C@@H](S)C2)COCC=2C(=CC(F)=C(F)C=2)F)=N1 AYBXHWXTWCIHTP-NWDGAFQWSA-N 0.000 claims 1
- QRPSWQVMTOZSIC-DOTOQJQBSA-N (3r,5s)-1-(2-phenoxypyrimidin-4-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=C(OC=3C=CC=CC=3)N=CC=2)C[C@H](S)C1 QRPSWQVMTOZSIC-DOTOQJQBSA-N 0.000 claims 1
- TVYWICRWPUGEFD-NWDGAFQWSA-N (3r,5s)-1-(4,6-dimethoxypyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound COC1=CC(OC)=NC(N2[C@@H](C[C@@H](S)C2)COCC=2C(=CC(F)=C(F)C=2)F)=N1 TVYWICRWPUGEFD-NWDGAFQWSA-N 0.000 claims 1
- ZBYVKAQKUFSUHI-VHSXEESVSA-N (3r,5s)-1-(4-amino-5-fluoropyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(N)=NC(N2[C@@H](C[C@@H](S)C2)COCC=2C(=CC(F)=C(F)C=2)F)=N1 ZBYVKAQKUFSUHI-VHSXEESVSA-N 0.000 claims 1
- CDWMLPFDROZTPB-DLBZAZTESA-N (3r,5s)-1-(5-pyridin-3-ylpyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=CC(=CN=2)C=2C=NC=CC=2)C[C@H](S)C1 CDWMLPFDROZTPB-DLBZAZTESA-N 0.000 claims 1
- VYOCXHUFKWXORO-DLBZAZTESA-N (3r,5s)-1-(5-pyridin-4-ylpyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=CC(=CN=2)C=2C=CN=CC=2)C[C@H](S)C1 VYOCXHUFKWXORO-DLBZAZTESA-N 0.000 claims 1
- UVUJLMKBKHBROX-JKSUJKDBSA-N (3r,5s)-1-(5-thiophen-3-ylpyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=CC(=CN=2)C2=CSC=C2)C[C@H](S)C1 UVUJLMKBKHBROX-JKSUJKDBSA-N 0.000 claims 1
- WERIMYMQPAGYPE-ZWKOTPCHSA-N (3r,5s)-1-[2-(benzylamino)pyrimidin-4-yl]-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=C(NCC=3C=CC=CC=3)N=CC=2)C[C@H](S)C1 WERIMYMQPAGYPE-ZWKOTPCHSA-N 0.000 claims 1
- JBISUVFYOSMVQM-LSDHHAIUSA-N (3r,5s)-1-[2-(butylamino)pyrimidin-4-yl]-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound CCCCNC1=NC=CC(N2[C@@H](C[C@@H](S)C2)COCC=2C(=CC(F)=C(F)C=2)F)=N1 JBISUVFYOSMVQM-LSDHHAIUSA-N 0.000 claims 1
- YBZULUMQYLZWJD-NWDGAFQWSA-N (3r,5s)-1-[2-(methylamino)pyrimidin-4-yl]-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound CNC1=NC=CC(N2[C@@H](C[C@@H](S)C2)COCC=2C(=CC(F)=C(F)C=2)F)=N1 YBZULUMQYLZWJD-NWDGAFQWSA-N 0.000 claims 1
- UNKNXSFMYAROAL-PKOBYXMFSA-N (3r,5s)-1-[5-(4-methoxyphenyl)pyrimidin-2-yl]-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=CC(OC)=CC=C1C1=CN=C(N2[C@@H](C[C@@H](S)C2)COCC=2C(=CC(F)=C(F)C=2)F)N=C1 UNKNXSFMYAROAL-PKOBYXMFSA-N 0.000 claims 1
- ANQXBYLDYFYYSO-NWDGAFQWSA-N (3r,5s)-1-pyrazin-2-yl-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=CC=NC=2)C[C@H](S)C1 ANQXBYLDYFYYSO-NWDGAFQWSA-N 0.000 claims 1
- UZYXKNUYXAPBRV-JHEYCYPBSA-N (3r,5s)-1-pyridin-2-yl-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=CC=CC=2)C[C@H](S)C1 UZYXKNUYXAPBRV-JHEYCYPBSA-N 0.000 claims 1
- HCAPHMKDDMUESA-DLBZAZTESA-N (3r,5s)-5-[(2,4,5-trifluorophenyl)methoxymethyl]-1-[5-(2-trimethylsilylethynyl)pyrimidin-2-yl]pyrrolidine-3-thiol Chemical compound N1=CC(C#C[Si](C)(C)C)=CN=C1N1[C@H](COCC=2C(=CC(F)=C(F)C=2)F)C[C@@H](S)C1 HCAPHMKDDMUESA-DLBZAZTESA-N 0.000 claims 1
- VPNROZRRPDMWDL-QWHCGFSZSA-N (3r,5s)-5-[(2,5-difluoro-4-methoxyphenyl)methoxymethyl]-1-(2-methoxypyrimidin-4-yl)pyrrolidine-3-thiol Chemical compound COC1=NC=CC(N2[C@@H](C[C@@H](S)C2)COCC=2C(=CC(OC)=C(F)C=2)F)=N1 VPNROZRRPDMWDL-QWHCGFSZSA-N 0.000 claims 1
- CDWMLPFDROZTPB-UHFFFAOYSA-N 1-(5-pyridin-3-ylpyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COCC1N(C=2N=CC(=CN=2)C=2C=NC=CC=2)CC(S)C1 CDWMLPFDROZTPB-UHFFFAOYSA-N 0.000 claims 1
- UVUJLMKBKHBROX-UHFFFAOYSA-N 1-(5-thiophen-3-ylpyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound C1=C(F)C(F)=CC(F)=C1COCC1N(C=2N=CC(=CN=2)C2=CSC=C2)CC(S)C1 UVUJLMKBKHBROX-UHFFFAOYSA-N 0.000 claims 1
- UWDUECVRFKOQKX-VZXYPILPSA-N 2,2,2-trifluoroacetic acid;(3r,5s)-1-[4-(trifluoromethyl)pyrimidin-2-yl]-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidine-3-thiol Chemical compound OC(=O)C(F)(F)F.C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2N=C(C=CN=2)C(F)(F)F)C[C@H](S)C1 UWDUECVRFKOQKX-VZXYPILPSA-N 0.000 claims 1
- WUEPMEXUMQVEGN-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;2,2,2-trifluoro-n-[2-[2-[(2,2,2-trifluoroacetyl)amino]ethylamino]ethyl]acetamide Chemical compound OC(=O)C(F)(F)F.FC(F)(F)C(=O)NCCNCCNC(=O)C(F)(F)F WUEPMEXUMQVEGN-UHFFFAOYSA-N 0.000 claims 1
- JSFXXFMQIMIOTA-UONOGXRCSA-N 2-[(2s,4r)-4-sulfanyl-2-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidin-1-yl]pyridine-3-carbonitrile Chemical compound C1=C(F)C(F)=CC(F)=C1COC[C@H]1N(C=2C(=CC=CN=2)C#N)C[C@H](S)C1 JSFXXFMQIMIOTA-UONOGXRCSA-N 0.000 claims 1
- LXTWYFDYKSBOCX-NWDGAFQWSA-N 2-[(2s,4r)-4-sulfanyl-2-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidin-1-yl]pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1N1[C@H](COCC=2C(=CC(F)=C(F)C=2)F)C[C@@H](S)C1 LXTWYFDYKSBOCX-NWDGAFQWSA-N 0.000 claims 1
- BWNXXAWAZSGSRS-NWDGAFQWSA-N 2-[(2s,4r)-4-sulfanyl-2-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidin-1-yl]pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1N1[C@H](COCC=2C(=CC(F)=C(F)C=2)F)C[C@@H](S)C1 BWNXXAWAZSGSRS-NWDGAFQWSA-N 0.000 claims 1
- ADZVOMVMIAGCJA-ZWKOTPCHSA-N 4-[2-[(2s,4r)-4-sulfanyl-2-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidin-1-yl]pyrimidin-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CN=C(N2[C@@H](C[C@@H](S)C2)COCC=2C(=CC(F)=C(F)C=2)F)N=C1 ADZVOMVMIAGCJA-ZWKOTPCHSA-N 0.000 claims 1
- BNDSAUJQUBQEMB-NWDGAFQWSA-N 6-methyl-2-[(2s,4r)-4-sulfanyl-2-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidin-1-yl]pyrimidine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=NC(N2[C@@H](C[C@@H](S)C2)COCC=2C(=CC(F)=C(F)C=2)F)=N1 BNDSAUJQUBQEMB-NWDGAFQWSA-N 0.000 claims 1
- 239000005973 Carvone Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000006287 difluorobenzyl group Chemical group 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- TZVFQFLWFZUIQS-UHFFFAOYSA-N pyrrolidine-3-thiol Chemical compound SC1CCNC1 TZVFQFLWFZUIQS-UHFFFAOYSA-N 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- FRYMCZDMUBETNT-DLBZAZTESA-N s-[(3r,5s)-1-(5-propylpyrimidin-2-yl)-5-[(2,4,5-trifluorophenyl)methoxymethyl]pyrrolidin-3-yl] ethanethioate Chemical compound N1=CC(CCC)=CN=C1N1[C@H](COCC=2C(=CC(F)=C(F)C=2)F)C[C@@H](SC(C)=O)C1 FRYMCZDMUBETNT-DLBZAZTESA-N 0.000 claims 1
- ZJAMIEIOACGWIT-RBUKOAKNSA-N s-[(3r,5s)-5-[[(2,5-difluorophenyl)methylamino]methyl]-1-(5-propylpyrimidin-2-yl)pyrrolidin-3-yl] ethanethioate Chemical compound N1=CC(CCC)=CN=C1N1[C@H](CNCC=2C(=CC=C(F)C=2)F)C[C@@H](SC(C)=O)C1 ZJAMIEIOACGWIT-RBUKOAKNSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 125000006510 trifluorobenzyl group Chemical group 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010059109 Cerebral vasoconstriction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00114950 | 2000-07-19 | ||
| PCT/EP2001/008059 WO2002006271A1 (en) | 2000-07-19 | 2001-07-12 | Pyrimidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004504317A JP2004504317A (ja) | 2004-02-12 |
| JP2004504317A5 true JP2004504317A5 (https=) | 2005-02-03 |
| JP3983662B2 JP3983662B2 (ja) | 2007-09-26 |
Family
ID=8169227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002512174A Expired - Lifetime JP3983662B2 (ja) | 2000-07-19 | 2001-07-12 | ピリミジン誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6660738B2 (https=) |
| EP (1) | EP1303507A1 (https=) |
| JP (1) | JP3983662B2 (https=) |
| KR (1) | KR100551853B1 (https=) |
| CN (1) | CN1443184A (https=) |
| AR (1) | AR030940A1 (https=) |
| AU (1) | AU2001285836A1 (https=) |
| BR (1) | BR0112656A (https=) |
| CA (1) | CA2415681C (https=) |
| MX (1) | MXPA03000504A (https=) |
| PA (1) | PA8522201A1 (https=) |
| PE (1) | PE20020484A1 (https=) |
| UY (1) | UY26845A1 (https=) |
| WO (1) | WO2002006271A1 (https=) |
| ZA (1) | ZA200300161B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8088737B2 (en) | 2003-04-04 | 2012-01-03 | Incyte Corporation | Compositions, methods and kits relating to Her-2 cleavage |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2276750A2 (en) * | 2008-03-27 | 2011-01-26 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
| MA38287B1 (fr) | 2013-01-23 | 2018-08-31 | Astrazeneca Ab | Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0182213B1 (en) * | 1984-11-08 | 1990-09-26 | Sumitomo Pharmaceuticals Company, Limited | Carbapenem compounds and production thereof |
| AU631671B2 (en) * | 1989-08-04 | 1992-12-03 | Banyu Pharmaceutical Co., Ltd. | 2-(2-vinylpyrrolidinylthio)carbapenem derivatives |
| US5360798A (en) * | 1991-07-04 | 1994-11-01 | Shionogi Seiyaku Kabushiki Kaisha | Aminooxypyrrolidinylthiocarbapenem compounds |
| US5317016A (en) * | 1991-08-20 | 1994-05-31 | Shionogi Seiyaku Kabushiki Kaisha | Pyrrolidylthiocarbapenem derivative |
| CA2227829A1 (en) * | 1995-07-31 | 1997-02-13 | Shionogi & Co., Ltd. | Pyrrolidine derivatives having phospholipase a2 inhibitory activity |
| CN1221417A (zh) * | 1996-07-26 | 1999-06-30 | 雷迪博士研究基金会 | 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物 |
| BR9712792A (pt) * | 1996-08-28 | 1999-12-14 | Procter & Gamble | Inibidores de metaloprotease bidentada. |
| EP1015431B1 (en) * | 1997-09-12 | 2005-04-20 | Merck Frosst Canada & Co. | 2-aminopyridines as inhibitors of cyclooxygenase-2 |
| US6329418B1 (en) * | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
-
2001
- 2001-07-12 KR KR1020037000727A patent/KR100551853B1/ko not_active Expired - Fee Related
- 2001-07-12 JP JP2002512174A patent/JP3983662B2/ja not_active Expired - Lifetime
- 2001-07-12 EP EP01965123A patent/EP1303507A1/en not_active Withdrawn
- 2001-07-12 MX MXPA03000504A patent/MXPA03000504A/es active IP Right Grant
- 2001-07-12 WO PCT/EP2001/008059 patent/WO2002006271A1/en not_active Ceased
- 2001-07-12 BR BR0112656-3A patent/BR0112656A/pt not_active IP Right Cessation
- 2001-07-12 CA CA002415681A patent/CA2415681C/en not_active Expired - Fee Related
- 2001-07-12 AU AU2001285836A patent/AU2001285836A1/en not_active Abandoned
- 2001-07-12 CN CN01812970A patent/CN1443184A/zh active Pending
- 2001-07-16 PA PA20018522201A patent/PA8522201A1/es unknown
- 2001-07-16 PE PE2001000709A patent/PE20020484A1/es not_active Application Discontinuation
- 2001-07-17 UY UY26845A patent/UY26845A1/es not_active Application Discontinuation
- 2001-07-17 US US09/906,983 patent/US6660738B2/en not_active Expired - Fee Related
- 2001-07-17 AR ARP010103414A patent/AR030940A1/es unknown
-
2003
- 2003-01-07 ZA ZA200300161A patent/ZA200300161B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11691969B2 (en) | Pyridazinones as PARP7 inhibtors | |
| KR101668574B1 (ko) | 브루톤 티로신 키나제 억제제 | |
| IL324078A (en) | Fused ring compounds | |
| JP2012501312A5 (https=) | ||
| TWI736566B (zh) | Ｔｌｒ７/８拮抗劑及其用途 | |
| RU2644151C2 (ru) | Гетероциклические соединения и их применение | |
| CN114072397A (zh) | 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法 | |
| JP2010500414A5 (https=) | ||
| CN110256427A (zh) | 2-(吗啉-4-基)-1,7-萘啶 | |
| JP2011520896A5 (https=) | ||
| HUE035553T2 (hu) | Aminopirimidinil-vegyületek mint JAK-inhibitorok | |
| WO2008064116A2 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| TW201625592A (zh) | 苯甲基取代吲唑 | |
| US20210317092A1 (en) | Tetrazole containing compounds | |
| WO2018206547A1 (en) | Combination of bub1 and atr inhibitors | |
| JP2021535137A5 (https=) | ||
| EP3558960B1 (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| JP2004504297A5 (https=) | ||
| US8841302B2 (en) | HCV inhibitor and therapeutic agent combinations | |
| JP2004504317A5 (https=) | ||
| JP2004504379A5 (https=) | ||
| CA3212314A1 (en) | Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma | |
| JP2009515950A5 (https=) | ||
| US9655887B2 (en) | Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception | |
| US12023319B2 (en) | Carboxylic acid aromatic amides |